Clinical Trial: A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

U.S., April 26 -- ClinicalTrials.gov registry received information related to the study (NCT06385925) titled 'A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation' on April 18.

Brief Summary: The study is a first-in-human (FIH), open-label, multi-center phase 1/2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors. This study will consist of a phase 1 dose escalation part and phase 2 dose expansion part.

Study Type: Interventional

Condition: Malignant Neoplasm

Intervention: Drug: TSN1611

TSN1611 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.

Recruitment Status: Recruiting

Published by HT Digital Content Services w...